Breast Cancer

Dr. Julia White from Community Memorial Hospital Discusses Exceptions in the Z11 Trial

Joyce A. O'Shaughnessy explores the 8th Annual School of Breast Oncology, an interactive program designed to immerse oncology professionals in the latest science.

The Z11 study suggests that there is no difference in survival among patients with breast cancer who did not undergo a recommended surgical treatment.

The FDA commissioner announced the withdrawal of its approval for bevacizumab (Avastin) to treat patients with breast cancer.

Dr. Adam Brufsky from the University of Pittsburgh School of Medicine Advises Doctors on Bevacizumab (Avastin) for Breast Cancer

Dr. Beth DuPree from Holy Redeemer Health System Provides Z11 Trial Takeaway Points

Dr. Julia R. White from the Medical College of Wisconsin, Discusses the Z11 Trial Radiation Findings

Dr. Adam Brufsky from University of Pittsburgh School of Medicine, Discusses Bevacizumab Benefits in TNBC

The following cases were discussed at the 10th International Congress on the Future of Breast Cancer, which was held in Coronado, California, from August 4-7, 2011.

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Dr. Lori Goldstein from Fox Chase Cancer Center on the Fox Chase Breast Evaluation Center

Older patients with breast cancer who have a history of heart disease and/or diabetes have an increased risk of cardiotoxicity during treatment with trastuzumab.

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

Dr. Wayne Bardwell from UCSD Cancer Center on Cancer-Related Variables and Depression

The controversy over the breast cancer indication for Avastin culminated in June when the ODAC voted after an unusual and emotional 2-day hearing to uphold a prior recommendation to withdraw the label indication.

Dr. Hope S. Rugo from the University of California, San Francisco on the Efficacy of Bevacizumab in Breast Cancer

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Discusses the Z11 Trial Focus on Morbidity

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

HER2-positive women can be effectively treated with Herceptin (trastuzumab injection) without the use of Adriamycin.

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab

Leading breast cancer researcher Joyce A. O'Shaughnessy, MD, developed and chaired the 10th International Congress on the Future of Breast Cancer, a 4-day interactive program.

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker